Another RICOdiculous Decision
Drug & Device Law
JULY 24, 2023
Yet what the plaintiffs were claiming is that, despite Actos’ undisputed effectiveness as a diabetes treatment, no TPP in the country would have purchased it for that purpose because of the 3/10,000 bladder cancer increased risk. at *6 (plaintiff “has documents and formularies reaching back to only 2009”). PATDC82 I , 943 F.3d
Let's personalize your content